Tyenne

Understanding Tyenne® 

Tyenne® (tocilizumab-aazg) is a biosimilar to Actemra® (tocilizumab), functioning as an interleukin-6 (IL-6) receptor antagonist. It is approved for the treatment of several inflammatory conditions, including:

• Moderately to Severely Active Rheumatoid Arthritis (RA): For adult patients who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs).

• Giant Cell Arteritis (GCA): For adult patients with this condition.

• Polyarticular Juvenile Idiopathic Arthritis (PJIA): For patients aged 2 years and older.

• Systemic Juvenile Idiopathic Arthritis (SJIA): For patients aged 2 years and older.

How Tyenne® Works:

• IL-6 Receptor Blockade: Tocilizumab-aazg binds to IL-6 receptors, inhibiting the cytokine’s role in inflammation.

• Reduction of Inflammatory Activity: By blocking IL-6 signaling, Tyenne® decreases inflammation, alleviating symptoms associated with RA, GCA, PJIA, and SJIA.

• Administration: Tyenne® offers both intravenous (IV) and subcutaneous (SC) administration options:

  • Rheumatoid Arthritis (RA): For IV administration, the recommended dosage is 4 mg/kg every 4 weeks, which may be increased to 8 mg/kg based on clinical response. For SC administration, patients under 100 kg should receive 162 mg every other week, with the possibility of increasing to every week based on response; patients 100 kg or more should receive 162 mg every week.

  • Giant Cell Arteritis (GCA): For IV administration, 6 mg/kg every 4 weeks in combination with a tapering course of glucocorticoids. For SC administration, 162 mg once every week, also in combination with a tapering course of glucocorticoids.

  • Polyarticular Juvenile Idiopathic Arthritis (PJIA): For IV administration, patients under 30 kg should receive 10 mg/kg every 4 weeks; those 30 kg or more should receive 8 mg/kg every 4 weeks. For SC administration, patients under 30 kg should receive 162 mg once every 3 weeks; those 30 kg or more should receive 162 mg once every 2 weeks.

  • Systemic Juvenile Idiopathic Arthritis (SJIA): For IV administration, patients under 30 kg should receive 12 mg/kg every 2 weeks; those 30 kg or more should receive 8 mg/kg every 2 weeks. For SC administration, patients under 30 kg should receive 162 mg every 2 weeks; those 30 kg or more should receive 162 mg every week.

FDA Approval:

• Tyenne® was approved by the U.S. Food and Drug Administration (FDA) on March 7, 2024, as a biosimilar to Actemra® for the treatment of RA, GCA, PJIA, and SJIA.

For more information, please visit the Tyenne® patient website and speak with your healthcare provider to determine if Tyenne® is the right treatment option for you.